Table 9.
Distribution of Histopathologically-Confirmed Brain and Other Central Nervous System Tumors by WHO Grade Completeness, Treatment Information Completeness, and Histopathology, CBTRUS Statistical Report: US Cancer Statistics – NPCR and SEER, 2015-2019
| Histopathology | Number of Newly Diagnosed Tumors | Histopathologically-Confirmed (%)a | WHO Grade Completeness (%)b | Assigned WHO Gradec | Radiation Information Completenessd (%) | Surgical Extent of Resection Information Completenesse(%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete | Incomplete | Not Applicable | WHO Grade I | WHO Grade II | WHO Grade III | WHO Grade IV | |||||
| Diffuse Astrocytic and Oligodendroglial Tumors | 84,012 | 94.3% | 90.9% | 9.1% | 0.1% | 0.5% | 10.8% | 12.9% | 75.8% | 59.0% | 99.6% |
| Diffuse astrocytoma | 7,634 | 92.5% | 84.3% | 15.6% | 0.1% | 2.8% | 71.9% | 15.6% | 9.8% | 44.7% | 99.4% |
| Anaplastic astrocytoma | 7,046 | 99.3% | 94.1% | 5.9% | 0.1% | 0.2% | 2.2% | 89.6% | 8.0% | 69.1% | 99.6% |
| Glioblastoma | 63,258 | 93.6% | 91.1% | 8.8% | 0.1% | 0.2% | 0.2% | 0.7% | 98.9% | 60.6% | 99.7% |
| Oligodendroglioma | 3,687 | 96.9% | 92.4% | 7.6% | 0.0% | 1.4% | 89.2% | 7.7% | 1.7% | 38.2% | 99.5% |
| Anaplastic oligodendroglioma | 1,871 | 99.1% | 93.6% | 6.4% | 0.1% | 0.0% | 4.3% | 89.9% | 5.8% | 64.6% | 99.6% |
| Oligoastrocytic tumors | 516 | 97.3% | 91.2% | 8.8% | 0.0% | 1.5% | 43.0% | 46.3% | 9.2% | 61.8% | 99.8% |
| Other Astrocytic Tumors | 6,252 | 86.4% | 86.9% | 12.8% | 0.4% | 86.4% | 9.7% | 3.3% | 0.7% | 6.5% | 99.7% |
| Pilocytic astrocytoma | 5,339 | 87.9% | 87.2% | 12.4% | 0.4% | 95.3% | 3.7% | 0.6% | 0.4% | 4.9% | 99.8% |
| Unique astrocytoma variants | 913 | 77.5% | 84.5% | 15.4% | 0.1% | 25.8% | 50.5% | 21.2% | 2.5% | 15.8% | 99.4% |
| Malignant | 532 | 97.9% | 87.7% | 12.1% | 0.2% | 3.1% | 66.0% | 27.7% | 3.3% | 24.4% | 99.4% |
| Non-Malignant | 381 | 49.1% | 75.4% | 24.6% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.8% | 99.5% |
| Ependymal Tumors | 6,911 | 86.2% | 88.0% | 12.0% | 0.1% | 36.8% | 48.0% | 14.3% | 0.9% | 23.0% | 99.7% |
| Malignant | 3,909 | 93.4% | 89.5% | 10.4% | 0.1% | 2.6% | 73.4% | 22.7% | 1.3% | 34.2% | 99.9% |
| Non-Malignant | 3,002 | 76.9% | 85.5% | 14.4% | 0.0% | 93.6% | 5.9% | 0.2% | 0.3% | 7.8% | 99.5% |
| Other Gliomas | 8,854 | 41.7% | 51.9% | 47.1% | 1.0% | 10.3% | 22.8% | 19.5% | 47.3% | 26.4% | 99.3% |
| Glioma malignant, NOS | 8,753 | 41.1% | 51.7% | 47.3% | 1.0% | 10.3% | 21.7% | 19.6% | 48.4% | 26.3% | 99.3% |
| Other neuroepithelial tumors | 101 | 92.1% | 58.1% | 41.9% | 0.0% | 10.9% | 61.8% | 18.2% | 9.1% | 33.8% | 98.9% |
| Malignant | 60 | 98.3% | 44.1% | 55.9% | 0.0% | 14.8% | 29.6% | 37.0% | 18.5% | 43.5% | 98.3% |
| Non-Malignant | 41 | 82.9% | 82.4% | 17.6% | 0.0% | 7.1% | 92.9% | 0.0% | 0.0% | 17.9% | 100.0% |
| Neuronal and Mixed Neuronal-Glial Tumors | 5,339 | 91.7% | 65.7% | 19.5% | 14.8% | 82.8% | 13.5% | 2.8% | 0.9% | 12.9% | 99.6% |
| Malignant | 960 | 98.3% | 26.9% | 5.6% | 67.6% | 28.7% | 7.0% | 51.0% | 13.4% | 53.5% | 99.3% |
| Non-Malignant | 4,379 | 90.3% | 76.3% | 23.3% | 0.4% | 85.7% | 13.9% | 0.3% | 0.2% | 3.9% | 99.7% |
| Choroid Plexus Tumors | 827 | 87.4% | 76.8% | 23.1% | 0.1% | 64.8% | 20.9% | 13.6% | 0.7% | 3.9% | 99.4% |
| Malignant | 121 | 96.7% | 76.9% | 22.2% | 0.9% | 7.7% | 4.4% | 83.5% | 4.4% | 11.2% | 100.0% |
| Non-Malignant | 706 | 85.8% | 76.7% | 23.3% | 0.0% | 75.9% | 24.1% | 0.0% | 0.0% | 2.7% | 99.3% |
| Tumors of the Pineal Region | 769 | 79.2% | 42.1% | 0.0% | 57.9% | 0.0% | 100.0% | 0.0% | 0.0% | 39.1% | 99.5% |
| Malignant | 462 | 97.8% | 42.9% | 0.0% | 57.1% | 0.0% | 100.0% | 0.0% | 0.0% | 59.4% | 99.3% |
| Non-Malignant | 307 | 51.1% | 39.6% | 0.0% | 60.4% | --% | --% | --% | --% | 7.6% | 100.0% |
| Embryonal Tumors | 3,170 | 98.4% | 82.5% | 16.8% | 0.6% | 0.5% | 0.3% | 1.1% | 98.1% | 58.4% | 99.9% |
| Tumors of Cranial and Spinal Nerves | 37,048 | 48.1% | 43.8% | 56.2% | 0.0% | 99.4% | 0.3% | 0.1% | 0.2% | 14.2% | 99.4% |
| Nerve sheath tumors | 37,015 | 48.1% | 43.8% | 56.2% | 0.0% | 99.4% | 0.3% | 0.1% | 0.2% | 14.2% | 99.4% |
| Malignant | 211 | 83.9% | 22.6% | 77.4% | 0.0% | 57.5% | 12.5% | 20.0% | 10.0% | 32.2% | 98.3% |
| Non-Malignant | 36,804 | 47.9% | 44.0% | 56.0% | 0.0% | 99.6% | 0.3% | 0.0% | 0.1% | 14.1% | 99.4% |
| Other tumors of cranial and spinal nerves | 33 | 42.4% | 28.6% | 71.4% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% |
| Tumors of Meninges | 184,405 | 37.4% | 80.5% | 19.5% | 0.1% | 79.9% | 18.0% | 2.0% | 0.1% | 6.1% | 99.6% |
| Meningiomas | 178,447 | 36.2% | 82.2% | 17.8% | 0.0% | 80.1% | 18.3% | 1.5% | 0.1% | 5.9% | 99.5% |
| Malignant | 1,615 | 78.1% | 88.1% | 11.9% | 0.0% | 20.4% | 15.0% | 63.6% | 1.0% | 34.4% | 98.5% |
| Non-Malignant | 176,832 | 35.8% | 82.1% | 17.9% | 0.0% | 81.4% | 18.4% | 0.2% | 0.1% | 5.6% | 99.6% |
| Mesenchymal tumors | 5,815 | 75.4% | 57.1% | 42.0% | 0.8% | 77.1% | 10.4% | 11.8% | 0.7% | 11.9% | 99.6% |
| Malignant | 766 | 96.3% | 42.8% | 53.2% | 4.1% | 11.3% | 14.4% | 70.2% | 4.1% | 47.5% | 99.5% |
| Non-Malignant | 5,049 | 72.3% | 60.1% | 39.7% | 0.2% | 86.6% | 9.8% | 3.3% | 0.2% | 6.3% | 99.6% |
| Primary melanocytic lesions | 143 | 88.1% | 11.9% | 83.3% | 4.8% | 60.0% | 13.3% | 6.7% | 20.0% | 35.0% | 99.2% |
| Malignant | 89 | 94.4% | 8.3% | 84.5% | 7.1% | 42.9% | 0.0% | 14.3% | 42.9% | 44.8% | 98.8% |
| Non-Malignant | 54 | 77.8% | 19.0% | 81.0% | 0.0% | 75.0% | 25.0% | 0.0% | 0.0% | 21.4% | 100.0% |
| Lymphomas and Hematopoietic Neoplasms | 8,525 | 94.9% | 1.9% | 97.3% | 0.8% | 84.3% | 1.3% | 4.6% | 9.8% | 16.5% | 99.0% |
| Lymphoma | 8,482 | 94.9% | 1.9% | 97.5% | 0.6% | 84.2% | 1.3% | 4.6% | 9.9% | 16.3% | 99.1% |
| Other hematopoietic neoplasms | 43 | 97.7% | 2.4% | 64.3% | 33.3% | 100.0% | 0.0% | 0.0% | 0.0% | 64.7% | 95.2% |
| Germ Cell Tumors | 1,280 | 86.6% | 8.8% | 43.4% | 47.8% | 18.8% | 7.8% | 7.8% | 65.6% | 53.5% | 99.0% |
| Malignant | 1,110 | 88.6% | 8.7% | 40.6% | 50.6% | 1.9% | 9.4% | 9.4% | 79.2% | 60.4% | 99.2% |
| Non-Malignant | 170 | 74.1% | 9.4% | 65.4% | 25.2% | 100.0% | 0.0% | 0.0% | 0.0% | 7.7% | 97.6% |
| Tumors of Sellar Region | 79,996 | 43.9% | 14.2% | 0.4% | 85.5% | 100.0% | 0.0% | 0.0% | 0.0% | 2.5% | 99.5% |
| Tumors of the pituitary | 76,863 | 42.3% | 11.8% | 0.0% | 88.2% | 100.0% | 0.0% | 0.0% | 0.0% | 1.8% | 99.5% |
| Malignant | 108 | 63.9% | 8.0% | 0.0% | 92.0% | -- | -- | -- | -- | 17.7% | 97.1% |
| Non-Malignant | 76,755 | 42.3% | 11.8% | 0.0% | 88.2% | 100.0% | 0.0% | 0.0% | 0.0% | 1.8% | 99.5% |
| Craniopharyngioma | 3,133 | 83.1% | 37.0% | 4.0% | 59.0% | 100.0% | 0.0% | 0.0% | 0.0% | 20.1% | 99.6% |
| Unclassified Tumors | 18,404 | 16.8% | 8.5% | 83.4% | 8.1% | 80.1% | 5.7% | 3.7% | 10.6% | 3.3% | 95.6% |
| Hemangioma | 4,215 | 28.3% | 8.7% | 91.0% | 0.3% | 97.1% | 2.9% | 0.0% | 0.0% | 1.4% | 98.7% |
| Neoplasm, unspecified | 13,647 | 11.9% | 8.1% | 77.1% | 14.8% | 68.1% | 7.8% | 7.8% | 16.4% | 4.1% | 92.7% |
| Malignant | 6,693 | 8.5% | 7.2% | 87.3% | 5.6% | 27.0% | 10.8% | 18.9% | 43.2% | 6.6% | 89.4% |
| Non-Malignant | 6,954 | 15.1% | 8.6% | 71.6% | 19.7% | 87.3% | 6.3% | 2.5% | 3.8% | 2.7% | 94.5% |
| All other | 542 | 50.2% | 9.9% | 87.5% | 2.6% | 65.4% | 7.7% | 0.0% | 26.9% | 3.3% | 99.3% |
| Malignant | 59 | 94.9% | 31.6% | 63.2% | 5.3% | 47.1% | 11.8% | 0.0% | 41.2% | 25.0% | 100.0% |
| Non-Malignant | 483 | 44.7% | 4.2% | 94.0% | 1.9% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 99.1% |
| TOTAL | 445,792 | 53.4% | 65.7% | 19.1% | 15.2% | 40.4% | 14.1% | 7.7% | 37.7% | 17.9% | 99.5% |
| Malignant | 126,345 | 85.8% | 79.7% | 18.5% | 1.9% | 5.8% | 13.1% | 13.6% | 67.5% | 48.5% | 99.5% |
| Non-Malignant | 319,447 | 40.5% | 54.4% | 19.6% | 26.0% | 84.2% | 15.4% | 0.3% | 0.1% | 5.7% | 99.5% |
aHistopathologic confirmation includes tumors classified as diagnosis confirmed by positive histopathology, positive cytology, positive histopathology plus – positive immunophenotyping and/or positive genetic studies, or positive microscopic confirmation, method not specified.
bCompleteness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer's Collaborative Staging schema, SSDI Clinical Grade (2018+ only) or SSDI Pathological Grade (2018+ only).
cGrade as recorded in the American Joint Commission on Cancer's Collaborative Staging schema, SSDI Clinical Grade (2018+ only) or SSDI Pathological Grade (2018+ only). WHO grade may be reported according to 2007 or 2016 WHO classification depending on year of diagnosis, in which roman numerals are used to denote tumor grade.
dRadiation is defined using a recoded variable based on NAACCR Item #1360 (http://datadictionary.naaccr.org/default.aspx?c=10#136). Completeness is defined as having a value other than 'none' or 'unknown.'
eSurgery is defined using a recoded variable based on NAACCR Item #1290 (http://datadictionary.naaccr.org/default.aspx?c=10#1290). Please see the SEER site-specific surgery codes for more information on coding for this variable. (https://seer.cancer.gov/archive/tools/SEER2003.surg.prim.site.codes.pdf). Completeness is defined as having a value other than 'unknown.'
-- Percentages are not presented when category is not applicable.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; WHO, World Health Organization.